Topic:

M&A

Latest Headlines

Latest Headlines

J&J hints at 'bold steps' in device deals in 2016, details 5 device collaborations

After disclosing a major restructuring of its medical device business last week, Johnson & Johnson tried to refocus on the future of that group on its annual earnings call. It emphasized doing more deals to acquire platforms for growth, as well as funneling more resources to high revenue growth device groups.

Indian pharma mulls deal for U.S. injectables maker Sagent Pharma

U.S. injectables maker Sagent Pharmaceuticals is considering putting itself on the chopping block, and if or when it does, at least 5 Indian drugmakers could come calling.

Struggling XenoPort rumored to consider a sale

XenoPort, a month removed from deep job cuts, is looking to sell itself, according to Reuters, reaching out to potential acquirers after a string of R&D disappointments.

BioClinica buys into cost management with its latest deal

Acquisitive CRO BioClinica bought a firm that specializes in handling the financial side of clinical trials, picking up technology that automates how sponsors and contractors pay for studies.

Medicines Co. jumps on rumors of a multibillion-dollar buyout

Drugmaker the Medicines Company saw its shares rise as high as 14% on rumors that the company may be up for sale.

Acorda bags PhIII Parkinson's drug in $363M Biotie buyout

Acorda Therapeutics has swooped in to buy Finland's Biotie for $363 million in cash, snagging a Phase III Parkinson's drug that is being lined up to follow its leading experimental drugs into the neurology market.

Second activist investor buys 5% stake in HeartWare, putting Valtech deal in doubt

HeartWare's acquisition of Israeli cardiac implant maker Valtech Cardio is now in even greater jeopardy. Reuters reports that a second group of activist investors, led by former J.P. Morgan CFO Doug Braunstein, purchased a 5% stake in the struggling company in hopes of blocking the transaction.

JPM: Don't expect any splashy device acquisitions from J&J

Johnson & Johnson ($JNJ) CEO Alex Gorsky struck a skeptical tone when it comes to large M&A deals at the J.P. Morgan Healthcare Conference in San Francisco, stressing the company's desire to return money to shareholders, including about 50% in the form of dividends.

Biotech rehearses its 'difficult' second album at #JPM16

The two most commonly watched indexes of biotech stocks have each fallen more than 35% from their July peaks, battered down by a pervasive sense that the frothy days of the biotech boom, when becoming "the Amgen of" anything seemed at least glancingly possible, have passed. And that sentiment permeated this year's J.P. Morgan Healthcare Conference.

Pfizer expands consumer biz in China with Treerly supplements buy

Pfizer's consumer health unit is said to be destined for sale, but that doesn't mean the business has stopped making its own buys. The drug giant snapped up Treerly Health, the China-based subsidiary of Sirio Pharma, and its portfolio of nutritional products for women, Pfizer said Thursday.
'